Dean Elhag, MD

I am interested in understanding and effectively treating cancer | Hematology Oncology Physician with GU oncology focus.

[Yüksel Ürün @DrYukselUrun]

📢 Big win for a rare kidney cancer subtype!
In HLRCC-associated papillary RCC, bevacizumab + erlotinib delivered a 72% response rate and median PFS of 21.1 months.
🧬 Germline FH-mutated pRCC finally gets a targeted shot.
#Oncology #RCC #HLRCC #KidneyCancer #PrecisionMedicine @NEJM @kidneycan @IKCCorg @KidneyCancer @eric_facs @OncoAlert @OncBrothers @medicalwatchBC
https://t.co/SacMGfXN5h

[Goutham Sunny @medoncodoc]

Out in NEJM!!

🚨 Breakthrough in HLRCC-associated RCC!
A Phase 2 trial shows that 💉bevacizumab + erlotinib offers high efficacy in advanced papillary renal cell carcinoma:

🔬 HLRCC-associated pRCC:
✅ 72% response rate
⏱️ Median PFS: 21.1 mo
💀 Median OS: 44.6+ mo

🔬 Sporadic pRCC:
✅ 35% response rate
⏱️ PFS: 8.9 mo
💀 OS: 18.2 mo

💊 Common AEs: rash (93%), diarrhea (89%), proteinuria (78%)
⚠️ Grade ≥3 AEs: HTN (34%), proteinuria (17%)

📢 Effective option for a disease with limited therapies!

10.1056/NEJMoa2200900

@DrChoueiri @urotoday @DrRosenbergMSK @BradMcG04 @DrKarineTawagi @DrRanaMcKay @MattGalsky @BhardwajLab @sonpavde @nataliagandur @drgaganprakash @vedangmurthy @paulobergerot @andreanecchi @tapiajc1 @drenriquegrande @SScagliarini_ @tompowles1 @shilpaonc @pgrivasmdphd @albertobossial @montypal @albigesL

[Sandeep Gurram @SandeepGurramMD]

Excited to share our work performed at @theNCI addressing needs of rare hereditary kidney cancer through bench to bedside work

Bevacizumab + erlotinib for #HLRCC assoc RCC
📍Response rate 72%
📍mPFS 21.1 mo

Thanks to the patients who supported the study!
https://t.co/lJhRgR0ejb

[Rohan Garje, MD @RohanGarjeMD]

🚨 New @ASCO Guideline on #mCRPC just published!
Glad to co-author recs on sequencing, #PARP inhibitors, #genomics, chemo & radiopharmaceuticals
Grateful to expert panel
@BryanRumble @IrbazRiaz #RahulParikh @AlanBryce9 @JCO_ASCO @OncoAlert @OncLive
🔗https://t.co/eDA6j6VewH

[Abhijit Das, MD @AbhijitSurgPath]

Kidney tumors - updates & newer entities (Basic facts for residents)

Molecularly defined entities involving TFE3, TFEB, ELOC, ALK, SMARCB1, SDH, FH etc. Evolving classification of papillary renal cell carcinoma.

#MakeSurgiPathEasy
#RenalTumorsUpdates

[Kidney Cancer @KidneyCancer]

UPDATE 3/12: Last night the House voted to cut 57% of federally funded medical and cancer research through the CDMRP. Vote moves on to Senate and, if passed, to be signed into law by the President.

More details: https://t.co/N2E4n1pfTd

[HLRCC Foundation @HLRCCFoundation]

Mizzou wrestler raises awareness of HLRCC genetic disorder that led to his own battle with cancer https://t.co/mm3smM8vzZ via @komunews

[HLRCC Foundation @HLRCCFoundation]

Our first HLRCC Symposium is in the books and we are excited to share an online version for those interested in learning more about the condition. Special thank you to all those who contributed @FrezzaLab @MuellerRom @LauraEsfeller @MarstonLinehan https://t.co/BzkQEQTCkX

[GU Oncology Now @GUOncologyNow]

🔍 Check out this study investigating the molecular subtypes of #fumarate #hydratase-deficient #RCC.

📚 Read More: https://t.co/tqJEaXNUun

[Kidney Cancer @KidneyCancer]

Congrats @LauraEsfeller on detailing the #HLRCC journey and how to move the field forward! Fantastic addition to today’s first HLRCC Symposium. Register: https://t.co/aB6wiFcVL0 #kidneycancer #rarecancer #raredisease #worldkidneycancerday @HLRCCFoundation @ERAkidney @EuRefNetwork

[Kidney Cancer @KidneyCancer]

And you can register for the upcoming #HLRCC Symposium 2024 on June 20 from 12-2 pm EST, hosted by our Affiliate Partner @HLRCCFoundation with @ERAkidney @EuRefNetwork. Register free for this virtual webinar: https://t.co/aB6wiFcVL0
#rarecancer #worldkidneycancerday

[Kidney Cancer @KidneyCancer]

Our Affiliate Partner @HLRCCFoundation with @ERAkidney @EuRefNetwork are conducting a survey to estimate the # of #HLRCC patients and treatment centers. Learn more and take the brief survey here: https://t.co/nSlzpWgdrr

[Udhayvir Grewal @UGrewalMD]

Thrilled to share our @UIowaCancer experience with repeat beta PRRT 🦓. Link-https://t.co/Nh8hErEsGB
So grateful to my mentors Dr @ChandrikhaC and Dr Dillon. I’m geared up for more exciting research from our NET team.

[HLRCC Foundation @HLRCCFoundation]

Virtual HLRCC Symposium! June 20 @ 12 - 2 PM est. Physician scientists & patient perspective talks including @LauraEsfeller Register & share: https://t.co/Rb0oK7fEwZ
@KidneyCancer @IKCCorg @FrezzaLab @KimrynRathmell @markballmd @KidneyCancerDoc

[Mark Ball, MD, FACS @markballmd]

Given dx of HLRCC and fantastic imaging from @aamalayeri & #MarkAhlman @NIHRadiology, we proceeded to radical nephrectomy. Multiple FH-deficient tumors lining the cyst wall.

#HLRCC is a different disease: have to dismiss most of the dogma for ccRCC. Cystic dz can still be bad.

[Yousef Zakharia @ZakhariaYousef]

Thank you @GUOncologyNow for highlighting our recent @NatureComms paper IIT through @BigTenCRC @AlvaAjjai @eric_facs @MonikaJoshimd @RohanGarjeMD @UIowaCancer @IntMedatIowa

Epigenetic Regulation for Immune Evasion in Advanced Kidney Cancer https://t.co/u5pXgghi66

[Internal Medicine at Iowa @IntMedatIowa]

Neeraj Agarwal, MD, FASCO, is a professor of medicine at the @UUtah @huntsmancancer Institute. He was invited by Yousef Zakharia, MD, onto the Iowa campus last week to deliver a Grand Rounds presentation and to meet with residents and fellows. https://t.co/H4nmvVDWH9

[GU Pathology Society (GUPS) @GU_Path_Society]

**GUPS Virtual Education Series is back with a new exciting topic**

Topic: Hereditary Renal Cell Carcinoma When: 4/11/2024
Time: 12-1:45PM EST

Register at Zoom link below

https://t.co/4MQYNcIhiF

[Kidney Cancer @KidneyCancer]

Thanks to Dr. Ramaprasad Srinivasan and @apolo_andrea for discussing how @theNCI is tackling rare #kidneycancer tumors. Read more on our blog: https://t.co/BJ9n9NvX5u

#rarecancer #cancerresearch #kidneycancerawarenessmonth

[Iovance Biotherapeutics @IovanceBio]

The @US_FDA has granted accelerated approval for our therapy for advanced melanoma.
Learn more: https://t.co/02ZyLG8HPi